Ditemukan 35083 dokumen yang sesuai dengan query :: Simpan CSV
Background: There was still limited data whether sarcopenia related to chemotherapy toxicity and impacted to quality of life. The aim is to know the role of sarcopenia on chemotherapy toxicity and changed of quality of life after breast cancer patients. Methods: This prospective cohort study was conducted in breast cancer women patients with age 18 to 59-year old who underwent chemotherapy, will be evaluated sarcopenia with Bio-Impedans analysis and JAMAR dynamometer. Evaluation of chemotherapy toxicity and quality of life with National cancer institute common toxicity criteria and European Organization for research and treatment of cancer care quality of life 30 and BRE-23. Results: A total of 128 breast cancer subjects with median age 47(25-59) year old, 39.1% with obese, 56.3% with stage 2 disease. Sarcopenia before chemotherapy associated with toxicities after first, second, and third cycles of chemotherapy with adjusted OR 1.73(0.62-4.86); 40.34(2.54-641.19); and 3.98(0.14-114.01), respectively. Sarcopenia associated with changed of quality of life scores of loss of appetite, constipation, and financial loss domains with adjusted OR 2.23(0.27-18.63), 3.42(0.75-15.50), and 5.50(1.41-21.42) respectively after underwent three cycles of chemotherapy. Conclusion: Sarcopenia before chemotherapy associated with chemotherapy toxicity and decreased quality of life score for several domain of symptom scales
Kanker payudara merupakan kanker yang paling banyak diderita oleh wanita di dunia, khususnya di Indonesia. Pengobatan yang lama dan berat memiliki dampak psikologis yang berpengaruh terhadap kualitas hidup pasien. Dukungan sosial penting untuk kualitas hidup pasien kanker payudara. Penelitian ini bertujuan untuk menganalisis pengaruh dukungan sosial terhadap kualitas hidup pasien kanker payudara di Rumah Sakit Kanker Dharmais. Penelitian ini menggunakan pendekatan kuantitatif dengan desain studi longitudinal dan kualitatif dengan case study. Sampel penelitian ini adalah pasien kanker payudara yang berobat dan tercatat pada di RS Kanker Dharmais periode bulan Agustus-Desember 2023 yang memenuhi syarat kriteria inklusi dan eksklusi penelitian sebanyak 190 pasien. Pengukuran kualitas hidup dengan kuesioner EORTC QLQ 30 dan BR-23 Pengukuran dukungan sosial dengan kuesioner Multidimensional Scale of Perceived Social Support (MSPSS). Pengumpulan data kualitatif dengan kelompok focus group discussion (FGD) dan wawancara mendalam. Analisis data menggunakan analisis regresi logistik untuk pengukuran data berulang pada data kategorik dengan General Estimation of Equotion (GEE). Dukungan sosial mempengaruhi kualitas hidup pasien kanker payudara sebesar 3,9 kali (OR=3,9; 95% CI: 3,3-4,6) setelah dikontrol faktor umur dan stadium kanker payudara. Sumber dukungan yang paling berpengaruh yaitu dukungan keluarga (OR=5,2 CI 95% 2,8-7,6) dan tenaga kesehatan (OR=2,0 CI 95% 1,3-3,1). Bentuk dukungan sosial yang paling berpengaruh yaitu dukungan emosional (OR=5,3 CI 95% 3,0-9,0), nyata (OR=3,6 CI 95% 2,5-5,2), dan informasi (OR=2,4 CI 95% 1,4-4,3). Pengaruh dukungan sosial terhadap kualitas hidup berdasarkan waktu terdapat penurunan seiring berjalannya waktu. Diharapkan untuk peningkatan dukungan sosial dari keluarga, tanaga Kesehatan dalam bentuk dukungan emosianal, nyata dan informasi. Rumah Sakit Kanker Dharmais juga diharapkan untuk mengoptimalkan program paliatif dan NAPAK sebagai bentuk dukungan sosial terhadap pasien kanker payudara. Kata Kunci : Kualitas Hidup, Dukungan Sosial, Pasien Kanker Payudara
Breast cancer is the most common type of cancer affecting women worldwide, particularly in Indonesia. The lengthy and intensive treatment process often has psychological impacts that affect patients' quality of life. Social support plays a crucial role in improving the quality of life of breast cancer patients. This study aims to analyze the effect of social support on the quality of life of breast cancer patients at Dharmais Cancer Hospital. A mixed-methods design was used, combining a quantitative longitudinal approach with a qualitative case study. The sample consisted of 190 breast cancer patients who were treated and registered at Dharmais Cancer Hospital between August and December 2023, and who met the study's inclusion and exclusion criteria. Quality of life was measured using the EORTC QLQ-C30 and BR-23 questionnaires, while social support was assessed using the Multidimensional Scale of Perceived Social Support (MSPSS). Qualitative data were collected through focus group discussions (FGDs) and in-depth interviews. Data were analyzed using logistic regression for repeated measurements, employing the Generalized Estimating Equation (GEE) method for categorical data. The results showed that social support significantly influenced the quality of life of breast cancer patients, increasing the odds by 3.9 times (OR = 3.9; 95% CI: 3.3–4.6) after controlling for age and cancer stage. The most influential sources of support were family (OR = 5.2; 95% CI: 2.8–7.6) and healthcare workers (OR = 2.0; 95% CI: 1.3–3.1). The most impactful forms of support were emotional (OR = 5.3; 95% CI: 3.0–9.0), tangible (OR = 3.6; 95% CI: 2.5–5.2), and informational support (OR = 2.4; 95% CI: 1.4–4.3). However, the effect of social support on quality of life was found to decrease over time. It is therefore recommended to enhance social supports particularly from family and healthcare professionals through emotional, tangible, and informational forms. Dharmais Cancer Hospital is also expected to optimize its palliative care and NAPAK programs as a structured form of social support for breast cancer patients. Keywords: Quality of Life, Social Support, Breast Cancer Patients
Latar belakang. Demam neutropenia merupakan salah satu adverse event yang sering terjadi pasien kanker payudara. Demam neutropenia yang tidak dapat dicegah dan ditangani dengan baik mengakibatkan komplikasi, kematian dan mempengaruhi efektivitas pengobatan. Olehkarena itu perlu diketahui faktor-faktor dominan apa saja yang dapat mempengaruhi terjadinya demam neutropenia agar kejadian demam neutropenia dapat dicegah. Tujuan. Untuk mengetahui hubungan variabel bebas usia, status performa, penyakit penyerta, jenis kanker payudara, stadium kanker payudara, pemberian kemoterapi sitotoksik, albumin, hemoglobin dengan kejadian demam neutropenia pada pasien kanker payudara di RS Kanker Dharmais Jakarta. Metode. Penelitian ini merupakan penelitian observasional dengan desain potong lintang. Hasil. Proporsi demam neutropenia adalah 13,67%. Faktor risiko dominan penyebab demam neutropenia adalah variabel status performa pasien PR Crude 3,64 (95% CI 2,07-6,39, p-value 0,001), PR Adjusted 2,16 (95% CI 1,09-4,30, p-value 0,027); diabetes PR Crude 2,30 (95% CI 1,21-4,53; p-value 0,012), PR Adjusted 2,17 (95%CI 1,07-4,41; p-value 0,030); stadium tiga PR Crude 2,28 (95% CI 1,2-5,07; p-value 0,001) PR Adjusted 2,49 (95% CI 1,11-5,60; p-value 0,001), dan stadium empat PR Crude 3,93 (95% CI 1,72-8,97; p-value 0,001) PR Adjusted 3,6 (95% CI 1,45-8,93; p-value 0,001). Kesimpulan. Kejadian demam neutropenia pada pasien kanker payudara menunjukkan hasil yang signifikan. Upaya pencegahan menggunakan profilaksis G-CSF diperlukan untuk pasien dengan risiko tinggi mengalami demam neutropenia. Penelitian lanjutan terkait konsekuensi demam neutropenia perlu dilakukan. Kata kunci. Demam neutropenia, faktor risiko, kanker payudara, kemoterapi sitotoksis
Background. Febrile neutropenia is one of the adverse events that often occur in breast cancer patients. If it cannot be prevented and treated properly, it increases complications and mortality and decreases the effectiveness of treatment. Therefore, knowing the dominant factors that can affect febrile neutropenia is necessary, and febrile neutropenia can be prevented. Objective. To determine the relationship between independent variables of age, performance status, comorbidities, type of breast cancer, stage of breast cancer, regiment of cytotoxic chemotherapy, albumin, and hemoglobin with the incidence of febrile neutropenia in breast cancer patients at Dharmais Cancer Hospital, Jakarta. Method. Observational study with cross-sectional design. Results. The proportion of febrile neutropenia was 13.67%. The dominant risk factors causing febrile neutropenia are patient performance status PR Crude 3,64 (95% CI 2,07-6,39, p-value 0,001), PR Adjusted 2,16 (95% CI 1,09-4,30, p-value 0,027); diabetes PR Crude 2,30 (95% CI 1,21-4,53; p-value 0,012), PR Adjusted 2,17 (95%CI 1,07-4,41; p-value 0,030); stages three of breast cancer PR Crude 2,28 (95% CI 1,2-5,07; p-value 0,001) PR Adjusted 2,49 (95% CI 1,11-5,60; p-value 0,001); stage four of breast cancer PR Crude 3,93 (95% CI 1,72-8,97; p-value 0,001) PR Adjusted 3,6 (95% CI 1,45-8,93; p-value 0,001). Conclusion. The incidence of febrile neutropenia in breast cancer patients showed significant results. Prophylaxis G-CSF is needed for patients at high risk of developing febrile neutropenia. Further research related to the consequences of febrile neutropenia is required. Keywords. Breast cancer, cytotoxic chemotherapy, febrile neutropenia, risk factors
Lymphedema is a chronic complication that commonly occurs after axillary lymph node dissection (ALND) in breast cancer patients. This study aimed to determine the incidence, risk factors, and prediction model for lymphedema after ALND in advanced-stage breast cancer patients. This was a retrospective cohort design on 174 patients at Dharmais Cancer Hospital. Cox regression was used to identify significant risk factors for lymphedema. The prediction accuracy of the model was assessed by calculating the area under the receiver operating characteristic curve (AUROC). The results showed that lymphedema was identified in 88/174 (50.6%) patients and most of them experienced lymphedema in the first 12 to 36 months after ALND. Risk factors associated with lymphedema include age, obesity, diabetes, neoadjuvant chemotherapy, and adjuvant chemotherapy. The prediction model showed good sensitivity (80.2%) in the study population with an AUC value of 0.706 (95% CI 0.629-0.783; p-value < 0.05). It can be concluded that the prediction model developed in this study is good enough to be implemented by clinicians in estimating the risk of lymphedema, especially for advanced-stage breast cancer patients in our hospital.
Infeksi HIV dan penyakit AIDS saat ini telah menjadi masalah kesehatan global. Sejak awal abad ke 21 peningkatan jumlah kasus semakin mencemaskan di Indonesia. Penyebaran infeksi HIV biasanya terjadi pada perilaku seksual, tetapi beberapa tahun belakangan ini resiko penularan lebih banyak terjadi pada pengguna narkoba suntik. Penelitian ini menggunakan desain studi kohort retrospektif dengan 164 sampel dan dilakukan selama juli-september 2012 yang bertujuan untuk mengetahui hubungan antara cara penularan terhadap ketahanan hidup 9 tahun pasien HIV/AIDS di RS Kanker Dharmais Jakarta Tahun 2003-2011 setelah dikontrol oleh variabel lain, dengan faktor confounding yaitu jumlah CD4, infeksi oportunistik, jenis kelamin, usia, status pernikahan, jenis pekerjaan, tingkat pendidikan dan daerah tempat tinggal. Data penelitian diperoleh melalui data rekam medis RS. Data dianalisis dengan menggunakan analisis survival metode kaplan meier dan dilanjutkan dengan analisis multivariat. Hasil penelitian menunjukkan bahwa probabilitas kumulatif ketahanan hidup secara umum pada pasien HIV/AIDS cukup baik. Terdapat hubungan yang signifikan antara kadar CD4 terhadap ketahanan hidup (nilai p=0,03) dan infeksi oportunistik terhadap ketahanan hidup (nilai p=0,00. Faktor infeksi oportunistik dan jumlah CD4 memiliki hubungan dengan cara penularan untuk mempengaruhi ketahanan hidup 9 tahun pasien HIV/AIDS dan terbukti sebagai faktor confounding. Sedangkan faktor counfounding lain tidak menunjukkan adanya hubungan terhadap ketahanan hidup 9 tahun pasien HIV/AIDS.
HIV and AIDS infection has been a pandemic health problem. Since the beginning of 21 century, case increasing in Indonesia has so disquiet. Infection transmission of HIV commonly happen to sexual activity, but the risk of transmission in drug user become more increase recently years.
Penelitian ini menggunakan metode analitik observasional dengan rancangan studi kohort retrospektif. Pengumpulan data dilakukan dengan mengikuti riwayat medis dan billing pasien penderita kanker payudara saat berobat ke Rumah Sakit Darmais pada periode tahun 2011 hingga 2016. Penelitian ini menggunakan analisis regresi logistik, survival dan evaluasi ekonomi dengan ICER (incremental cost effectiveness ratio) .
Hasil penelitian menunjukkan Pasien kanker payudara stadium lanjut lokal di RSK Dharmais yang menerima kemoterapi berbasis taksan memiliki risiko 1,516 kali lebih besar untuk mendapatkan respons klinis positif dibandingkan dengan pasien yang menerima kemoterapi berbasis antrasiklin. (RR adjusted 1,516; 95% CI: 0,601–3,826). Pasien dengan respon klinis yang negatif memiliki risiko kematian 1,7 kali lebih tinggi dibandingkan dengan pasien yang menunjukkan respon positif tstelah dikontrol oleh faktor perancu yaitu, jenis histopatologis dan stadium ( ajusted hazard ratio 1,729;95% CI: 1,031–2,902). Pasien kanker payudara stadium lanjut lokal (KPSLL) yang melakukan kemoterapi neadjuvan berbasis antrasiklin memiliki risiko 2 kali lipat lebih besar dibandingkan berbasis taksan untuk mengalami kematian setelah dikontrol oleh faktor perancu yaitu respon klinis, jenis istopatologis, stadium dan Subtipe molekular Luminal (adjusted hazard ratio 2,128 :95%CI:1,097-4,128). Nilai ICER (incremental cost effectiveness ratio) menunjukkan bahwa membutuhkan biaya sebesar Rp 3,1 juta untuk meningkatkan satu unit efektivitas (persentase jumlah pasien dengan respon klinis positif) dengan pemakaian regimen berbasis taksan dibandingkan dengan antrasiklin.
Hasil penelitian ini dapat menjadi dasar untuk melakukan Penilaian Teknologi Kesehatan dengan evaluasi ekonomi yang lebih komprehensif, khususnya dalam menilai intervensi kesehatan untuk penyakit kronis seperti kanker. Penelitian lanjutan diperlukan untuk lebih mendalami faktor-faktor perancu yang mungkin mempengaruhi hasil, seperti keterlambatan diagnosis dan pengobatan, riwayat terapi sebelumnya, dan status sosial ekonomi
Neoadjuvant chemotherapy is the standard treatment for locally advanced breast cancer (LABC). Contradictory findings exist regarding the effectiveness of two main types of neoadjuvant chemotherapy regimens, anthracycline and taxane, for treating LABC. At RSK Dharmais, anthracycline-based regimens are commonly used for LABC treatment. However, there is a lack of research on the clinical effectiveness and economic evaluation of anthracycline-based and taxane-based neoadjuvant chemotherapy regimens in patients with LABC at RSK Dharmais, Jakarta.
This study aims to assess the clinical effectiveness and economic evaluation of neoadjuvant chemotherapy for LABC at RSK Dharmais Jakarta from 2011 to 2016.
This study employed an observational analytic method with a retrospective cohort study design. Data collection was conducted by reviewing the medical records and billing data of breast cancer patients treated at RSK Dharmais during the 2011–2016 period. Logistic regression analysis, survival analysis, and economic evaluation using the Incremental Cost-Effectiveness Ratio (ICER) were performed.
Kata Kunci: Kanker payudara, kesintasan hidup, stadium kanker, RSCM
Based on GLOBOCAN data of 2012, the highest incidence of cancer in Indonesia is breast cancer. Currently there are still many deaths caused by breast cancer. The survival of breast cancer survivors depends on several factors that are very important to know, including the stage of cancer. This study aims to determine the effect of stage of cancer, age, education, occupation, marriage, health insurance status, family history, type of therapy and distance of residence to survival of breast cancer survivors. The study design used a retrospective cohort method. Samples in this study were 135 breast cancer patients who were first diagnosed with breast cancer from January 2007 to June 2012 at RS Cipto Mangunkusumo. Data analysis using SPSS program and Kaplan Meier method and related factors were analyzed with Cox regression. The results of bivariable analysis showed that the stage of cancer had a significant relationship to survival of breast cancer (p value = 0,000; HR 19,227 (95% CI 1,395-265,101)). While in the analysis of mutivariabel the relationship of stage to life survival is not significant (p value = 0,102) after controlled by education variable, work, therapy type and interaction of cancer stage with education of patient. The survival of breast cancer survivors in early stage of breast cancer was higher (94.1%) than those in advanced stage (70.1%). Patients with advanced stage 11 times higher risk than the early stage (HR = 10,923; 95% CI 0.623-191,417). So needed awareness and efforts to early detection of breast cancer to further improve survival of breast cancer patients.
Keywords: Breast cancer, life survival, cancer stage, RSCM
